{"id":"W3130387627","doi":"10.1158/1538-7445.sabcs20-pd14-03","title":"Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Paclitaxel; Breast cancer; Oncology; Cohort; Internal medicine; Immunohistochemistry; Cancer; Cyclin D1; Chemotherapy; Immune checkpoint; Triple-negative breast cancer; Cyclophosphamide; Cancer research; Cell cycle; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003807565,0.000305586,0.0005358559,0.0002437378,0.0002069518,0.0006938609,0.0004199937,0.0002983155,0.003721032],"category_scores_gemma":[0.0002871088,0.0002542158,0.0005049461,0.0002374672,0.0002425957,0.0003123537,0.0002476221,0.001052606,0.0005158655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007648435,"about_ca_system_score_gemma":0.0007937435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008468695,"about_ca_topic_score_gemma":0.002124396,"domain_scores_codex":[0.9998524,0.00003352383,0.000008050884,0.00003872046,0.00003459433,0.00003260248],"domain_scores_gemma":[0.9998888,0.00001473281,0.00003242719,0.00001189591,0.00001045802,0.00004166983],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1384845,0.01447984,0.1921988,0.0009089324,0.001036403,0.000843253,0.0003332909,0.00519948,0.3187887,0.0008903929,0.01153556,0.3153008],"study_design_scores_gemma":[0.027252,0.2204817,0.5807171,0.0001495616,0.001582481,0.00430313,0.000457114,0.01098172,0.1142001,0.001177501,0.03862796,0.00006959718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951298,0.00144104,0.0003506961,0.0002201568,0.00003658378,0.0002056119,0.001019374,0.00004148001,0.001555311],"genre_scores_gemma":[0.9954651,0.0006186177,0.0004365952,0.000154786,0.00002807142,0.0001498729,0.001581548,0.000008101956,0.001557223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003721032,"threshold_uncertainty_score":0.01244807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02802158427927248,"score_gpt":0.346558188338385,"score_spread":0.3185366040591125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}